Vivace Therapeutics Announces $30 Million Series C Financing to Fund Clinical Programs Targeting the Hippo Pathway

SAN MATEO, Calif., Dec. 16, 2020 -- (Healthcare Sales & Marketing Network) -- Vivace Therapeutics, Inc., a small molecule discovery and development company developing first-in-class therapies targeting the Hippo pathway, announced today the closing of a $... Biopharmaceuticals, Oncology, Venture Capital, Personnel Vivace Therapeutics, Hippo pathway
Source: HSMN NewsFeed - Category: Pharmaceuticals Source Type: news